Target repurposing for neglected diseases.

Infectious diseases are an enormous burden to global health and ,since drug discovery is costly, those infectious diseases that affect the developing world are often not pursued by commercial drug-discovery efforts. Therefore, pragmatic means by which new therapeutics can be discovered are needed. One such approach is target repurposing, where pathogen targets are matched with homologous human targets that have been pursued for drug discovery for other indications. In many cases, the medicinal chemistry, structural biology and biochemistry knowledge around these human targets can be directly repurposed to launch and accelerate new drug-discovery efforts against the pathogen targets. This article describes the overarching strategy of target repurposing as a tool for initiating and prosecuting neglected disease drug-discovery programs, highlighting this approach with three case studies.

[1]  Tom Blundell,et al.  A second front against AIDS , 1989, Nature.

[2]  W. M. Sanders,et al.  L-687,908, a potent hydroxyethylene-containing HIV protease inhibitor. , 1991, Journal of medicinal chemistry.

[3]  F. Kuzoe Current situation of African trypanosomiasis. , 1993, Acta tropica.

[4]  I B Duncan,et al.  Rational design of peptide-based HIV proteinase inhibitors. , 1990, Science.

[5]  M. Palmisano,et al.  Percutaneous Absorption and Pharmacokinetics of Eflornithine HC®l 13.9% Cream in Women with Unwanted Facial Hair , 2001, Journal of clinical pharmacology.

[6]  John P. Overington,et al.  Genomic-scale prioritization of drug targets: the TDR Targets database , 2008, Nature Reviews Drug Discovery.

[7]  A. Hopkins,et al.  The druggable genome , 2002, Nature Reviews Drug Discovery.

[8]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[9]  R. Mortara,et al.  The TryPIKinome of five human pathogenic trypanosomatids: Trypanosoma brucei, Trypanosoma cruzi, Leishmania major, Leishmania braziliensis and Leishmania infantum--new tools for designing specific inhibitors. , 2009, Biochemical and biophysical research communications.

[10]  James R. Brown,et al.  Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery , 2011, BMC Evolutionary Biology.

[11]  L J Davis,et al.  Active human immunodeficiency virus protease is required for viral infectivity. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Fairlamb Metabolic pathway analysis in trypanosomes and malaria parasites. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[13]  N. Grishin,et al.  X-ray structure of ornithine decarboxylase from Trypanosoma brucei: the native structure and the structure in complex with alpha-difluoromethylornithine. , 1999, Biochemistry.

[14]  J. Dimmock,et al.  Potential role of N-myristoyltransferase in cancer. , 2007, Progress in lipid research.

[15]  P. Darke,et al.  L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor. , 1994, Journal of medicinal chemistry.

[16]  J. Beavo,et al.  Cyclic nucleotide signaling mechanisms in trypanosomes: possible targets for therapeutic agents. , 2007, Molecular interventions.

[17]  S. Kunz,et al.  The Trypanosoma brucei cAMP phosphodiesterases TbrPDEBl and TbrPDEB2: flagellar enzymes that are essential for parasite virulence , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  J. Beavo,et al.  Cloning and characterization of a cAMP-specific phosphodiesterase (TbPDE2B) from Trypanosoma brucei , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[19]  N. Georgopapadakou Antifungals targeted to protein modification: focus on protein N-myristoyltransferase , 2002, Expert opinion on investigational drugs.

[20]  M. Navia,et al.  Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 , 1989, Nature.

[21]  Ian H. Gilbert,et al.  N-Myristoyltransferase inhibitors as new leads to treat sleeping sickness , 2010, Nature.

[22]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[23]  Els Torreele,et al.  Drug development for neglected diseases: a deficient market and a public-health policy failure , 2002, The Lancet.

[24]  K. Gull The cell biology of parasitism in Trypanosoma brucei: insights and drug targets from genomic approaches? , 2002, Current pharmaceutical design.

[25]  B. Dunn,et al.  Effective blocking of HIV‐1 proteinase activity by characteristic inhibitors of aspartic proteinases , 1989, FEBS letters.

[26]  J. Gordon,et al.  The Biology and Enzymology of ProteinN-Myristoylation* 210 , 2001, The Journal of Biological Chemistry.

[27]  H. Mett,et al.  Alterations in ornithine decarboxylase characteristics account for tolerance of Trypanosoma brucei rhodesiense to D,L-alpha-difluoromethylornithine , 1997, Antimicrobial agents and chemotherapy.

[28]  C. Chong,et al.  New uses for old drugs , 2007, Nature.

[29]  Minyong Li,et al.  Chemical Validation of Phosphodiesterase C as a Chemotherapeutic Target in Trypanosoma cruzi, the Etiological Agent of Chagas' Disease , 2010, Antimicrobial Agents and Chemotherapy.

[30]  Solomon Nwaka,et al.  Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.

[31]  A. D. Rodrigues,et al.  Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. , 1996, The Journal of pharmacology and experimental therapeutics.

[32]  Eileen Kraemer,et al.  PlasmoDB: a functional genomic database for malaria parasites , 2008, Nucleic Acids Res..

[33]  D. Goulding,et al.  Myristoyl-CoA:Protein N-Myristoyltransferase, an Essential Enzyme and Potential Drug Target in Kinetoplastid Parasites* , 2003, The Journal of Biological Chemistry.

[34]  P. McCann,et al.  Polyamine metabolism: a potential therapeutic target in trypanosomes. , 1980, Science.

[35]  S. Vasavanonda,et al.  ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Périé,et al.  Glycolysis and proteases as targets for the design of new anti-trypanosome drugs. , 2002, Current topics in medicinal chemistry.

[37]  D. Norbeck,et al.  Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. , 1990, Science.

[38]  L. Marton,et al.  Polyamines as targets for therapeutic intervention. , 1995, Annual review of pharmacology and toxicology.

[39]  R. Zoraghi,et al.  The cAMP-specific phosphodiesterase TbPDE2C is an essential enzyme in bloodstream form Trypanosoma brucei , 2002, Proceedings of the National Academy of Sciences of the United States of America.